BioPharma Dive March 4, 2024
Meg Richards, PhD, MBH Executive Director of Solutions, Panalgo With Mike Munsell, Director of Research, Panalgo

Sponsored content By Panalgo

In a rapidly evolving landscape where artificial intelligence (AI) and machine learning (ML) have become household terms, their impact on biopharmaceutical research and epidemiology is profound. I caught up with Mike Munsell, PhD, Director of Research at Panalgo, to discuss how these technologies are transforming the healthcare research landscape and their real-world applications in biopharmaceutical R&D. Classically trained epidemiologists know more about ML and AI than they think they do, and here’s why.

Q: We’re hearing more about AI, ML, and ChatGPT these days. Can you give me a definition of what each is and how they might overlap?

A: With AI, computers are essentially mimicking human decision-making. ML, a subdiscipline of AI, uses algorithms...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
Ingenious Self-Ask Prompting Technique Boosts Generative AI
How AI is making copyright issues more complicated | Devcom panel
Artificial intelligence method could advance gene mutation prediction in lung cancer
Yair Lotan, MD, on ethical considerations for AI in urology
Promise and Perils of AI in Medicine

Share This Article